Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Immutep
Biotech
Immutep's LAG-3 agent posts 'impressive' survival data
Immutep suggests that a high unmet need for first-line, PD-L1-negative HNSCC could potentially pave eftilagimod a path to approval.
Angus Liu
May 5, 2025 10:37am
Immutep regains pep as cancer subgroup data show path forward
Jul 12, 2024 9:35am
BMS CEO set to leave after 8-year run—Chutes & Ladders
Apr 28, 2023 9:30am
LAG-3-focused Immutep secures cash, plots new trial push
Jun 21, 2021 7:10am
SITC18: Merck highlights new LAG-3 and TIGIT data
Nov 7, 2018 11:05am
